Healthcare Provider Awareness and Integration of Immunotherapy for Stage III NSCLC

This poster, presented at the 2019 ASCO-SITC Clinical Immuno-Oncology Symposium, reports an analysis of healthcare provider uptake of immune checkpoint inhibitor therapy for the treatment of unresectable stage III NSCLC in the 9 months following its approval. Self-reported practice trends at baseline showed that most HCPs were not optimally treating unresectable stage III NSCLC prior to attending the symposia. However, post-education data suggest that HCPs are willing to modify their practice in this setting after receiving expert led education and guidance.


Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.


Cookie Settings